• Home
• Collaborations
• SR One

SR One

Applying insight. Creating value.

SR One is GlaxoSmithKline's independent corporate healthcare venture capital fund. The firm invests globally in emerging biotech companies that are pursuing innovative science which will significantly impact medical care. We have a team of investment professionals, located in the US and Europe. As a Team, our experience spans basic science, industry and the market.

We take an active role in our portfolio companies and work with management teams and our fellow venture investors to create significant value. Our current portfolio includes approximately 28 private and public companies and since our founding in 1985, we have invested over $600M in the biotech space.

Our expanded remit also focuses on maximizing the value of GSK technological innovation to establish new businesses and revenue opportunities across a range of industries.

Visit the SR One website to find out more.